Mauricio Mahave

Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma

Toni K. Choueiri, Piotr Tomczak, Se Hoon Park et al. · New England Journal of Medicine · 2021 · 746 citations · Full text

Medicine, Oncology, Pharmacotherapy +13

Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Thomas Powles, Piotr Tomczak, Se Hoon Park et al. · The Lancet Oncology · 2022 · 278 citations · Full text

Medicine, Oncology, Pharmacotherapy +16

Early versus deferred anti-SARS-CoV-2 convalescent plasma in patients admitted for COVID-19: A randomized phase II clinical trial

María Elvira Balcells, Luis Rojas, Nicole Le Corre et al. · PLoS Medicine · 2021 · 94 citations · Full text

Pharmacy, Internal Medicine, Pharmacotherapy +13

Systemic and Intracranial Outcomes With First-Line Nivolumab Plus Ipilimumab in Patients With Metastatic NSCLC and Baseline Brain Metastases From CheckMate 227 Part 1

Martin Reck, Tudor–Eliade Ciuleanu, Jong-Seok Lee et al. · Journal of Thoracic Oncology · 2023 · 72 citations · Full text

Medicine, Oncology, Pharmacology +17

Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for patients with renal cell carcinoma: Randomized, double-blind, phase III KEYNOTE-564 study.

Toni K. Choueiri, Piotr Tomczak, Se Hoon Park et al. · Journal of Clinical Oncology · 2021 · 38 citations

Medicine, Oncology, Perioperative Medicine +15